Therapeutic Management of Unresectable Stage III Non-small Cell Lung Cancer with Durvalumab

Non-small cell lung cancer (NSCLC) constitutes about 85% of all lung cancer cases.¹ Of those diagnosed with NSCLC in Hong Kong, approximately 13% are found to have stage III disease.² Prior to the advent of immunotherapy, the standard of care (SoC) involved concurrent chemoradiotherapy (cCRT) followed by active surveillance.³ However, outcomes have been poor, with most patients experiencing disease progression after CRT. This has resulted in a 5-year overall survival (OS) rate of 15–30% for stage III NSCLC.⁴